Bausch+Lomb releases Vyzulta
LAVAL, Quebec — Bausch+Lomb has begun rolling out Vyzulta (latanoprostene bunod ophthalmic solution 0.024%) to U.S. pharmaceutical distributors. The Valeant Pharmaceuticals International subsidiary said Vyzulta is slated to become available to patients at pharmacies across the United States in the next few days. The first prostaglandin analog with one of its metabolites being nitric oxide,
